Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis by 援ш탳泥� et al.
Journal of
Clinical Medicine
Article
Effect of Androgen-Deprivation Therapy on Bone
Mineral Density in Patients with Prostate Cancer:
A Systematic Review and Meta-Analysis
Do Kyung Kim 1 , Joo Yong Lee 2 , Kwang Joon Kim 3, Namki Hong 4, Jong Won Kim 2,
Yoon Soo Hah 1 , Kyo Chul Koo 1, Jae Heon Kim 5 and Kang Su Cho 1,*
1 Department of Urology, Gangnam Severance Hospital, Urological Science Institute, Yonsei University
College of Medicine, Seoul 06273, Korea; dokyung@yuhs.ac (D.K.K.); UROHAH@yuhs.ac (Y.S.H.);
GCKOO@yuhs.ac (K.C.K.)
2 Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of
Medicine, Seoul 03722, Korea; JOOURO@yuhs.ac (J.Y.L.); DOCTOR2PLAY@yuhs.ac (J.W.K.)
3 Division of Geriatrics, Department of Internal Medicine, Severance Hospital, Yonsei University College of
Medicine, Seoul 03722, Korea; PREPPIE@yuhs.ac
4 Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University
College of Medicine, Seoul 03722, Korea; NKHONG84@yuhs.ac
5 Department of Urology, Soonchunhyang University Hospital, Soonchunhyang University College of
Medicine, Seoul 04401, Korea; piacekjh@hanmail.net
* Correspondence: kscho99@yuhs.ac; Tel.: +82-2-2019-3471; Fax: +82-2-3462-8887
Received: 20 December 2018; Accepted: 15 January 2019; Published: 18 January 2019


Abstract: We aimed to evaluate the change in bone mineral density (BMD) in patients with prostate
cancer (PCa) receiving androgen deprivation therapy (ADT) compared to those with PCa or other
urologic conditions not receiving ADT. Literature searches were conducted throughout October 2018.
The eligibility of each study was assessed according to Preferred Reporting Items for Systematic
Reviews and Meta-Analyses guidelines using the Participant, Intervention, Comparator, Outcome,
and Study design method. The outcomes analyzed were the mean difference (MD) of percent changes
in BMD of lumbar spine, femur neck, and total hip. Five prospective cohort studies with a total of
533 patients were included in the present study. Statistically significant decreases of BMD change
relative to the control group were observed in the ADT treatment group in the lumbar spine (MD
−3.60, 95% CI −6.72 to −0.47, P = 0.02), femoral neck (MD −3.11, 95% CI −4.73 to −1.48, P = 0.0002),
and total hip (MD −1.59, 95% CI −2.99 to −0.19, P = 0.03). There is a significant relationship between
ADT and BMD reduction in patients with PCa. Regular BMD testing and the optimal treatment for
BMD loss should, therefore, be considered in patients with PCa undergoing ADT.
Keywords: androgen deprivation therapy; bone mineral density; prostate cancer; systematic review;
meta-analysis
1. Introduction
Prostate cancer (PCa) is the most common malignancy among men [1]. Improved screening and
management of the disease have led to earlier diagnosis and longer life expectancy for patients. Due to
the many side effects associated with treatment options, the quality of life for these patients is becoming
increasingly important [2]. Despite local treatment, the natural course of PCa in 40% of patients is
metastasis, especially in the bone [2]. Bone metastasis contributes to mortality and is the major cause
of morbidity due to skeletal-related events, including fractures and spinal cord compressions, and the
need for surgery or radiation therapy as therapeutic or palliative measures [3].
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PCa is an androgen-dependent disease, and androgen deprivation therapy (ADT) is the
mainstay of treatment for hormone-sensitive metastatic or advanced PCa [4]. In castrate-resistant
prostate cancer (CRPC), docetaxel chemotherapy and second-line hormone treatments, such as
abiraterone or enzalutamide, have been introduced. However, ADT must be maintained in CRPC [5].
Furthermore, patients with clinically localized PCa are usually treated with radical prostatectomy (RP),
radiation therapy (RT), or active surveillance [6]. Disease recurrence most often manifests as an increase
in prostate-specific antigen, so salvage therapy (RP, RT, cryoablation, high-intensity focused ultrasound
(HIFU)), and androgen deprivation therapy (ADT) were commonly applied in local recurrence of PCa [7].
ADT includes induction of hypogonadism through orchiectomy and a luteinizing hormone-releasing
hormone (LH-RH) agonist, alone or combined with an androgen blockade (LH-RH agonist plus
antiandrogen) [8]. Although ADT is highly effective, it can result in many problematic complications
related to long-term use, including osteoporosis with reduced bone mineral density (BMD) [9–11].
Undoubtedly, bone health is an important concern for patients with PCa. BMD may decrease by up
to 13% yearly in men receiving ADT [12]. Moreover, men with PCa may also experience significant
bone loss due to disease, even before the induction of ADT [6]. Since many patients with PCa tend to
be older, BMD loss is superimposed on the gradual decrease in bone density that accompanies normal
aging [13]. Cumulative decrease in BMD is related to an increased risk of fracture [14], which can
increase morbidity and mortality [15]. Diagnosed patients are susceptible to osteoporosis according
to their age, but most are receiving ADT [2]. These factors emphasize the fact that reduction in BMD
associated with ADT is becoming increasingly prevalent and important in patients with PCa.
Although numerous research studies have been conducted on the relationship between the use of
ADT and BMD reduction [9–11,16–22], there has not been a systematic review and meta-analysis of
this topic in existing literature. Therefore, we conducted this study as a systematic review of published
literature and meta-analysis of available data in order to evaluate the change in BMD in patients with
PCa receiving ADT compared to those who did not receive ADT.
2. Materials and Methods
This systematic review was registered in PROSPERO (CRD 42018107948).
2.1. Search Strategy
Computerized bibliographic search of PubMed or Medline, Embase, and Cochrane Library
databases was conducted through October 2018. Search terms included “prostate cancer”, “androgen
deprivation OR androgen suppression OR hormone OR gonadotropin” and “bone mineral density OR
bone loss OR bone density OR skeletal change OR osteoporosis”. Search terms used for PubMed or
Medline and Embase are listed in the Supplement section (File S1). Conference and meeting abstracts
were excluded, even if they met the eligibility criteria. In the end, our search identified 482 candidate
articles. Two authors (DKK and YSH) independently reviewed the titles and abstracts according to our
inclusion and exclusion criteria, and subsequently reviewed the identified articles.
2.2. Trial Inclusion and Exclusion Criteria
We assessed the eligibility of each study according to Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines using the Participant, Intervention, Comparator,
Outcome, and Study design (PICOS) method [23].
Study population was defined as patients with PCa who were treated with ADT. Patients with PCa
or other urologic conditions (e.g., benign prostatic hyperplasia, urologic stone, or erectile dysfunction)
who were not treated with ADT were defined as the comparator. The analyzed outcomes included
percent changes in BMD of lumbar spine, femur neck, and total hip. Inclusion criteria included a
study published in English, prospective cohort design, patients with PCa or other urologic diseases,
use of ADT, ADT duration of at least 6 months, follow-up period of at least 1 year, and reported
values for changes in BMD of lumbar spine, femur neck, or total hip. Exclusion criteria included a
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cohort observational study design (no control group), use of intermittent ADT regimen, a comparison
between regimens of ADT, short follow-up period (< 12 months), and inability to extract outcome data.
Conference and meeting abstract was also excluded.
2.3. Data Extraction
Two authors (DKK and YSH) reviewed all of the included articles and independently extracted
data from each study. Any discrepancies between the two authors in extracted data were resolved via
consensus. Extracted data included study design details, inclusion and exclusion criteria, participant
demographics, treatment characteristics (regimen, dosage, and duration), measured outcomes (BMD of
lumbar spine, femur neck, and total hip), and results (percent change of BMD, mean difference (MD),
and standard deviation (SD)).
2.4. Study Quality Assessments and Quality of Evidence
The quality of included clinical trials was evaluated according to the methodological index
of Downs and Black scale. This index is comprised of five major assessment categories,
including reporting, external validity, bias, confounding, and power [24].
Grading of Recommendations, Assessments, Developments, and Evaluation (GRADE) system
provided a systematic approach for evaluating the quality of evidence and strength of recommendations [25].
The certainty of comparisons was evaluated with GRADE system, using assessments of the following
criteria: methodology, precision, consistency, directness, and risk of publication bias. Based on these
criteria, we assessed evidence of comparisons by classifying the quality of evidence on a four-level
scale (i.e., high, moderate, low, and very low).
2.5. Statistical Analysis
Percent changes in BMD outcomes were measured and recorded as continuous data. Values of
MD and SD were extracted from all studies. The pooled MD for ADT and control group values and 95%
CIs were calculated. Meta-analyses were performed using the random-effects model of DerSimonian
and Laird to obtain pooled overall MD with 95% CIs for outcomes [26].
Statistical heterogeneity was assessed using I2 value and χ2 test. A Cochran Q statistic of P < 0.05
or I2 > 50% indicated the presence of statistically significant heterogeneity.
Meta-analysis was performed using Review Manager v.5.1 (Nordic Cochrane Center, Cochrane
Collaboration, Copenhagen, Denmark, 2008). All P-values were two-sided, and except for the test of
discrepancy, a P < 0.05 was considered to indicate a statistically significant result. Since fewer than
10 studies were included in our study, we did not follow through with a plan to use funnel plots to
assess small study effects.
3. Results
3.1. Systematic Review Process
We used PRISMA statements to analyze and summarize our systematic analysis and meta-review
process (Figure 1). Only published studies were included to minimize publication bias. Initial database
searches identified 2442 articles, which were reduced to 1778 following duplicate removal.
Subsequently, 1738 articles were removed after review of title and abstract. Analysis of the remaining
full-text articles, with respect to inclusion and exclusion criteria, resulted in the final selection of
five studies with a total of 533 patients (Table 1). All included studies were prospective cohort
studies. The majority of the study population were clinically localized or advanced PCa patients
who underwent ADT after diagnosis. The ADT in these studies included bilateral orchiectomy,
LH-RH agonist, and anti-androgen medication, and the duration of ADT ranged from 6 to 36 months.
The duration of follow-up ranged from 1 to 3 years. Excluded studies are listed in the Supplement
section (File S2).
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Figure 1. Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flowchart. This chart shows the flow of information through different phases
of systematic review and the exclusion criteria used.
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Table 1. Characteristics of eligible prospective cohort studies.
Study Design Group Characteristics (Total Number) Tumor Stage(Total Number)
Duration of
ADT
Follow-Up
Period
BMD Check
Site BMD Change Outcome (SD) Conflict of Interest
Alibhai et al.
[19]
prospective
cohort
study
ADT
Patients with PCa who underwent continuous ADT for at
least 1 year (80)
cT1c N0 M0 (22)
cT2 N0 M0 (41)
cT3 N0 M0 (17) 12–36
months
3 years
1. Lumbar
spine
2. Femoral
neck
3. Total hip
Lumbar
spine
ADT: −2.12% (7.2)
None
Control: −1.05% (4.7)
Femoral
neck
ADT: −1.99% (6.2)
Control Patients with PCa who were not on ADT (80)
cT1c N0 M0 (35)
cT2 N0 M0 (43)
cT3 N0 M0 (2)
Control: −0.95% (4.9)
Total hip ADT: −2.62% (4.1)
Control: 1.02% (4.0)
Bergstrom et
al. [9]
prospective
cohort
study
ADT
Patients with either advanced PCa or recurrent disease
following primary, local therapy who were treated with
bilateral orchidectomy and GnRH analogues
continuously (22)
NA
12 months 1 year Femoral
neck
ADT −3.9% (2.3)
Stiftelsen Johanna
Hagstrand och Sigfrid
Linne’rs Minne and
Karolinska Institutet
Research funds
Control Patients with other urologic conditions such as BPH,stones (40) NA Control −1.26% (3)
Morote et al.
[20]
prospective
cohort
study
ADT
Patients with PCa who underwent continuous ADT with
3 months of depot LH-RH agonist (31)
cT3a N0 M0 (14)
cT3b-4 N0 M0 (7)
cT2-4 N1 M0 (10)
12 months 1 year
1. Lumbar
spine
2. Femoral
neck
3. Total hip
Lumbar
spine
ADT: −4.8% (5)
None
Control: −0.82% (4.7)
Femoral
neck
ADT: −2.99% (3.9)
Control Patients with PCa free of BCR after RP (31)
cT1c N0 M0 (20)
cT2a N0 M0 (11)
Control: −0.64% (4.8)
Total hip ADT: −3.76% (4.7)
Control: −0.82% (4.4)
Preston et al.
[21]
prospective
cohort
study
ADT
Patients with PCa who had received continuous ADT for
a minimum of 6 months for either advanced PCa on
presentation or for recurrent disease following primary
local therapy (RP or RT) (39)
NA
≥6 months 2 years
1. Lumbar
spine
2. Femoral
neck
3. Total hip
Lumbar
spine
ADT: −0.2% (0.8)
U.S. Army Medical
Research and
Development
Command
Control: 1.1% (0.6)
Femoral
neck
ADT: −1.9% (0.7)
Control
Patients with other urologic conditions, such as ED or
BPH, and those with PCa who had completed primary
therapy (RP or RT) with no evidence of disease (39)
NA
Control: 0.6% (0.5)
Total hip ADT: −1.5% (1)
Control: −0.8% (0.5)
Ziaran et al.
[22]
prospective
cohort
study
ADT Patients with locally advanced PCa (95)
cT3a N0 M0 (89)
pT3b N0 M0 (6)
24 months 2 years
1. Lumbar
spine
2. Femoral
neck
3. Total hip
Lumbar
spine
ADT: −13.28% (1.8)
None
Control: −7.32% (1.7)
Femoral
neck
ADT: −17.14% (1.8)
Control
Patients with other urologic conditions such as LUTS,
stones, etc. (88) NA
Control: −9.27% (11.3)
Total hip ADT: 0% (2.7)
Control: 0% (2.6)
ADT, androgen deprivation therapy; BCR, biochemical recurrence; BMD, bone mineral density; BPH, benign prostate hyperplasia; ED, erectile dysfunction; LH-RH, luteinizing
hormone-releasing hormone; LUTS, lower urinary tract symptoms; NA, not available; PCa, prostate cancer; RP, radical prostatectomy; RT, radiation therapy; SD, standard deviation.
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3.2. Outcome Comparisons between ADT and Control Groups
3.2.1. Lumbar Spine: Percent Change of BMD
Analysis of the percent change of BMD in lumbar spine included four studies with 483 patients
(Figure 2A). A statistically significant decrease of lumbar spine BMD change was observed in ADT
group relative to control group (MD −3.60, 95% CI −6.72 to −0.47, P = 0.02). Between-study
heterogeneity was observed (I2 = 99%, P < 0.00001).
3.2.2. Femoral Neck: Percent Change of BMD
Analysis of the percent change of BMD in femoral neck included five studies with 515 patients
(Figure 2B). A statistically significant decrease of femoral neck BMD change was observed in ADT
group relative to control group (MD −3.11, 95% CI −4.73 to −1.48, P = 0.0002). Between-study
heterogeneity was observed (I2 = 82%, P = 0.0002).
3.2.3. Total Hip: Percent Change of BMD
Analysis of the percent change of BMD in total hip included four studies with 483 patients
(Figure 2C). A statistically significant decrease of BMD change of total hip was observed following
ADT treatment relative to control group (MD −1.59, 95% CI −2.99 to −0.19, P = 0.03). Between-study
heterogeneity was observed (I2 = 90%, P < 0.00001).
3.3. Quality Assessment and Qualitative Risk of Bias
Downs and Black scale was utilized to assess the quality of five prospective trials using reporting,
external validity, bias, confounding, and power assessment categories (Table 2). Downs and Black
scores of the evaluated studies ranged from 13 to 15. The results of GRADE quality assessment of
direct evidence of each comparison are shown in Table 3. Certainty was “low” in all three comparisons.
Table 2. Downs and Black scale for quality assessment.
Reporting External
Validity
Internal Validity
Power Total
Bias Confounding (Selection Bias)
Alibhai et al. [19] 7 1 3 3 1 15
Bergstrom et al. [9] 6 1 3 2 1 13
Morote et al. [20] 7 1 3 3 1 15
Preston et al. [21] 7 1 3 4 1 15
Ziaran et al. [22] 6 1 3 4 1 14
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Table 3. Grading of Recommendations, Assessments, Developments, and Evaluation (GRADE) quality assessment for direct evidence of each comparison.
Certainty Assessment Number of Patients Effect Certainty Importance
Number of
Studies Study Design Risk of Bias Inconsistency Indirectness Imprecision Other Considerations ADT Control
Absolute
(95% CI)
Lumbar spine
4 Prospective,cohort studies Not serious Serious
a Not serious Not serious Dose–response gradient 245 238 MD 3.6 lower(6.72 lower to 0.47 lower)
••##
LOW CRITICAL
Femoral neck
5 Prospective,cohort studies Not serious Serious
a Not serious Not serious Dose–response gradient 267 248 MD 3.11 lower(4.73 lower to 1.48 lower)
••##
LOW CRITICAL
Total hip
4 Prospective,cohort studies Not serious Serious
a Not serious Not serious Dose–response gradient 245 238 MD 1.59 lower(2.99 lower to 0.19 lower)
••##
LOW CRITICAL
ADT, androgen deprivation therapy; CI, confidence interval; MD, mean difference; a significant heterogeneity observed. LOW level of certainty means that further research is very likely to
have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
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4. Discussion
Healthy bone is in equilibrium with ongoing bone formation and bone resorption, which is
normally mediated by osteoblasts and osteoclasts [6]. Hormones, such as estrogens and androgens,
help balance this equilibrium between bone synthesis and degradation [27]. However, this equilibrium
is unbalanced in severely hypogonadal men, who experience decreased BMD and severe bone
architecture damage [28]. Unfortunately, ADT for PCa patients interferes with the normal hormonal
balance needed for bone health. The rate of BMD loss that occurs in patients receiving ADT is
significantly higher than that caused by normal aging or female menopause. Men experiencing normal
aging lose BMD at a rate of approximately 0.5% to 1.0% yearly until middle age. Women experiencing
normal aging lose bone mass at a similar rate until menopause, and then the rate of bone density
decline increases every year for 5 years (approximately 3% yearly in the spine). Bone loss associated
with ADT is more rapid and severe than that in normal aging men or women [6]. For example, the bone
loss rates in the lumbar spine and femoral neck regions of PCa patients after initiation of treatment
with ADT have been reported as 4.6% and 3.9% [17]. Numerous prospective studies have documented
the substantial bone loss that occurs in men with PCa who are treated with ADT [9–11,16–22]. To better
understand the findings of these studies, we examined the effects of ADT on BMD in PCa patients
through systematic review and meta-analysis of prospective cohort studies.
Our meta-analysis discerned a significant decline in BMD at the lumbar spine, femoral neck,
and total hip regions of PCa patients treated with ADT compared to controls. ADT causes a decrease
in BMD by affecting both the trabecular and cortical bones [29,30]. Bone loss due to ADT increases
the risk of fracture exponentially. Shahinian et al. [14] showed that among men surviving more
than 5 years after diagnosis of PCa, bone fractures were noted in about 20% of those who received
ADT, compared with about 10% of those who did not receive ADT (P < 0.001). These authors also
reported a significant relationship between the number of doses of LH-RH agonist administered during
the first year and fracture risk. Our analysis demonstrated a greater effect of ADT on BMD in the
lumbar spine than in the femoral neck or total hip, which is consistent with several other studies in
men who received ADT, in which decreases in lumbar spine BMD are greater than other measured
areas [20,31,32]. Lumbar spine has a higher percentage of trabecular bone than total hip or femoral
neck. Since trabecular bone is metabolically more active than cortical bone, it may be more sensitive
to ADT [19,33]. Moreover, lumbar spine is the most common site of fractures due to ADT, and BMD
reduction by ADT may be a predisposing factor to vertebral compression fractures [14,34].
Although it is clear that early detection of bone loss and prompt initiation of preventive and
pharmacological measures to delay or prevent decreased BMD are essential to reduce the risk of
bone fracture for advanced PCa patients who have begun ADT, clinical practice guidelines on BMD
evaluation in patients with PCa on ADT are not clear-cut [35]. Some suggestions have addressed
this issue. Diamond et al. [36] proposed that BMD should be assessed in patients considered to be
at high risk for osteoporosis and all men who have a risk factor for fracture, like those receiving
ADT or with a history of fracture. The USA Endocrine Society and the National Comprehensive
Cancer Network have proposed to measure BMD in men aged 50–69 years with risk factors
(e.g., ADT) [33,37]. National Comprehensive Cancer Network guidelines regarding ADT-induced
bone loss also recommend supplementation with either 60 mg of denosumab subcutaneously every
6 months, 5 mg of zoledronic acid intravenously every year, or 70 mg of alendronate orally every
week for men with a 10-year risk of hip fracture greater than 3%, calculated using the fracture
risk assessment tool [37,38]. Treatments for ADT-induced BMD loss include bisphosphonates,
human monoclonal antibody (denosumab), and selective estrogen receptor modulators (e.g., raloxifene
and toremifene) [39]. There have been many randomized controlled trials (RCTs) about the
efficacy of these osteoporotic medications for bone loss of PCa patients due to ADT. A systematic
review and network meta-analysis to compare the effectiveness of various osteoporotic treatments
(bisphosphonates, denosumab, toremifene, and raloxifene) on BMD loss in patients with non-metastatic
PCa on ADT, performed by Poon et al., [39], found that that all drugs are effective in reducing the
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rate of bone loss, but did not find evidence that one drug is more effective than another. Lifestyle
modifications and nutritional supplementation can have a significant effect on bone health, and may
delay the onset and severity of ADT-related bone loss. Regular exercise reduces the risk of fractures by
reducing bone loss, increasing bone and muscle strength, and improving mobility [40]. Nutritional
intervention is a simple way to determine whether a patient is receiving adequate levels of minerals and
vitamins, especially calcium and vitamin D, to maintain proper bone formation. Therefore, clinicians
administering ADT for PCa patients should always be mindful of periodic BMD testing. Moreover,
they should encourage lifestyle interventions and nutritional supplements, provide some form of
osteoporosis treatment to men who are at risk of fracture, and choose the optimal drug based on
efficacy, safety, patient preferences, patient and health system costs, and local availability [39].
Many meta-analyses have shown the effects of ADT on cognitive function, cardiovascular
complications, and thromboembolic events in PCa patients [41–45]; however, to the best of our
knowledge, our study is the first to show the effect of ADT on bone health in patients with
PCa. Furthermore, we have identified a significant relationship between ADT and BMD reduction.
The present study analyzed only prospective cohort studies, and the level of evidence was lower than
that of meta-analyses with only RCTs (level of evidence was evaluated using GRADE, and certainty
was low in all cases). Although only prospective cohort studies were included and inconsistency was
serious for all evidence, the level of evidence was elevated to “low” from “very low”, due to a strong
correlation between the duration of exposure to ADT and the decrease in BMD [46]. Control group of
the studies included in this analysis was heterogeneous. Control group included patients with PCa,
other urologic problems, or both. Other limitations of our analysis were the small number of included
studies and the inconsistency in the follow-up period of included studies.
5. Conclusions
There is a significant relationship between ADT and BMD reduction in patients with PCa.
Therefore, regular BMD testing should be considered in patients with PCa undergoing ADT. Moreover,
determination of the optimal treatment, such as medical therapy, lifestyle intervention, and nutritional
support for BMD loss based on various factors, should help identify patients who are at risk of fracture.
Well-designed prospective RCTs are required to overcome the limitations of this study, as well as to
establish evidence to support the results of the present study.
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File S1. Search terms; File S2. Excluded Studies.
Author Contributions: Conceptualization, D.K.K. and K.S.C.; methodology, J.Y.L.; validation, K.J.K., N.K.H., and
J.H.K.; formal analysis, D.K.K. and Y.S.H.; investigation, J.W.K.; resources, X.X.; data curation, D.K.K. and K.C.K.;
writing—original draft preparation, D.K.K.; writing—review & editing, K.S.C.; visualization, D.K.K.; supervision,
K.S.C. and J.H.K.; project administration, D.K.K.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277–300. [CrossRef]
[PubMed]
2. Bienz, M.; Saad, F. Androgen-deprivation therapy and bone loss in prostate cancer patients: A clinical review.
Bonekey Rep. 2015, 4, 716. [CrossRef] [PubMed]
3. So, A.; Chin, J.; Fleshner, N.; Saad, F. Management of skeletal-related events in patients with advanced
prostate cancer and bone metastases: Incorporating new agents into clinical practice. Can. Urol. Assoc. J.
2012, 6, 465–470. [CrossRef] [PubMed]
4. Koo, K.C.; Dasgupta, P. Treatment of oligometastatic hormone-sensitive prostate cancer: A comprehensive
review. Yonsei Med. J. 2018, 59, 567–579. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 113 11 of 13
5. Mohler, J.L.; Armstrong, A.J.; Bahnson, R.R.; D’Amico, A.V.; Davis, B.J.; Eastham, J.A.; Enke, C.A.;
Farrington, T.A.; Higano, C.S.; Horwitz, E.M.; et al. Prostate cancer, version 1.2016. J. Natl. Compr. Cancer
Netw. 2016, 14, 19–30. [CrossRef]
6. Eastham, J.A. Bone health in men receiving androgen deprivation therapy for prostate cancer. J. Urol.
2007, 177, 17–24. [CrossRef] [PubMed]
7. Park, J.W.; Jang, W.S.; Koh, D.H.; Ham, W.S.; Rha, K.H.; Hong, S.J.; Choi, Y.D. Impact of early salvage
androgen deprivation therapy in localized prostate cancer after radical prostatectomy: A propensity score
matched analysis. Yonsei Med. J. 2018, 59, 580–587. [CrossRef]
8. Sharifi, N.; Gulley, J.L.; Dahut, W.L. Androgen deprivation therapy for prostate cancer. JAMA
2005, 294, 238–244. [CrossRef]
9. Bergstrom, I.; Gustafsson, H.; Sjoberg, K.; Arver, S. Changes in bone mineral density differ between
gonadotrophin-releasing hormone analogue- and surgically castrated men with prostate cancer—A
prospective, controlled, parallel-group study. Scand. J. Urol. Nephrol. 2004, 38, 148–152. [CrossRef]
10. Berruti, A.; Dogliotti, L.; Terrone, C.; Cerutti, S.; Isaia, G.; Tarabuzzi, R.; Reimondo, G.; Mari, M.; Ardissone, P.;
De Luca, S.; et al. Changes in bone mineral density, lean body mass and fat content as measured by dual
energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given
androgen deprivation therapy. J. Urol. 2002, 167, 2361–2367. [CrossRef]
11. Daniell, H.W.; Dunn, S.R.; Ferguson, D.W.; Lomas, G.; Niazi, Z.; Stratte, P.T. Progressive osteoporosis during
androgen deprivation therapy for prostate cancer. J. Urol. 2000, 163, 181–186. [CrossRef]
12. Smith, M.R.; McGovern, F.J.; Zietman, A.L.; Fallon, M.A.; Hayden, D.L.; Schoenfeld, D.A.; Kantoff, P.W.;
Finkelstein, J.S. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
N. Engl. J. Med. 2001, 345, 948–955. [CrossRef] [PubMed]
13. Hussain, S.A.; Weston, R.; Stephenson, R.N.; George, E.; Parr, N.J. Immediate dual energy x-ray
absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before
hormonal manipulation. BJU Int. 2003, 92, 690–694. [CrossRef] [PubMed]
14. Shahinian, V.B.; Kuo, Y.F.; Freeman, J.L.; Goodwin, J.S. Risk of fracture after androgen deprivation for
prostate cancer. N. Engl. J. Med. 2005, 352, 154–164. [CrossRef] [PubMed]
15. Oefelein, M.G.; Ricchiuti, V.; Conrad, W.; Resnick, M.I. Skeletal fractures negatively correlate with overall
survival in men with prostate cancer. J. Urol. 2002, 168, 1005–1007. [CrossRef]
16. Mittan, D.; Lee, S.; Miller, E.; Perez, R.C.; Basler, J.W.; Bruder, J.M. Bone loss following hypogonadism in men
with prostate cancer treated with gnrh analogs. J. Clin. Endocrinol. Metab. 2002, 87, 3656–3661. [CrossRef]
17. Maillefert, J.F.; Sibilia, J.; Michel, F.; Saussine, C.; Javier, R.M.; Tavernier, C. Bone mineral density in men treated
with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J. Urol. 1999, 161, 1219–1222.
[CrossRef]
18. Eriksson, S.; Eriksson, A.; Stege, R.; Carlstrom, K. Bone mineral density in patients with prostatic cancer
treated with orchidectomy and with estrogens. Calcif. Tissue Int. 1995, 57, 97–99. [CrossRef]
19. Alibhai, S.M.; Mohamedali, H.Z.; Gulamhusein, H.; Panju, A.H.; Breunis, H.; Timilshina, N.; Fleshner, N.;
Krahn, M.D.; Naglie, G.; Tannock, I.F.; et al. Changes in bone mineral density in men starting androgen
deprivation therapy and the protective role of vitamin d. Osteoporos Int. 2013, 24, 2571–2579. [CrossRef]
20. Morote, J.; Orsola, A.; Abascal, J.M.; Planas, J.; Trilla, E.; Raventos, C.X.; Cecchini, L.; Encabo, G.; Reventos, J.
Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen
suppression. J. Urol. 2006, 175, 1679–1683. [CrossRef]
21. Preston, D.M.; Torrens, J.I.; Harding, P.; Howard, R.S.; Duncan, W.E.; McLeod, D.G. Androgen deprivation
in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis.
2002, 5, 304–310. [CrossRef] [PubMed]
22. Ziaran, S.; Goncalves, F.M.; Sn, J.B. Complex metabolic and skeletal changes in men taking long-term
androgen deprivation therapy. Clin. Genitourin. Cancer 2013, 11, 33–38. [CrossRef] [PubMed]
23. Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred
reporting items for systematic review and meta-analysis protocols (prisma-p) 2015 statement. Syst. Rev.
2015, 4. [CrossRef] [PubMed]
24. Downs, S.H.; Black, N. The feasibility of creating a checklist for the assessment of the methodological quality
both of randomised and non-randomised studies of health care interventions. J. Epidemiol. Community Health
1998, 52, 377–384. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 113 12 of 13
25. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gotzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.;
Kleijnen, J.; Moher, D. The prisma statement for reporting systematic reviews and meta-analyses of studies
that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009, 339, b2700. [CrossRef]
[PubMed]
26. DerSimonian, R.; Kacker, R. Random-effects model for meta-analysis of clinical trials: An update. Contemp.
Clin. Trials 2007, 28, 105–114. [CrossRef]
27. Leder, B.Z.; LeBlanc, K.M.; Schoenfeld, D.A.; Eastell, R.; Finkelstein, J.S. Differential effects of androgens and
estrogens on bone turnover in normal men. J. Clin. Endocrinol. Metab. 2003, 88, 204–210. [CrossRef]
28. Benito, M.; Gomberg, B.; Wehrli, F.W.; Weening, R.H.; Zemel, B.; Wright, A.C.; Song, H.K.; Cucchiara, A.;
Snyder, P.J. Deterioration of trabecular architecture in hypogonadal men. J. Clin. Endocrinol. Metab.
2003, 88, 1497–1502. [CrossRef]
29. Hamilton, E.J.; Ghasem-Zadeh, A.; Gianatti, E.; Lim-Joon, D.; Bolton, D.; Zebaze, R.; Seeman, E.; Zajac, J.D.;
Grossmann, M. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen
deprivation therapy. J. Clin. Endocrinol. Metab. 2010, 95, E456–E463. [CrossRef]
30. Cheung, A.S.; Zajac, J.D.; Grossmann, M. Muscle and bone effects of androgen deprivation therapy: Current
and emerging therapies. Endocr. Relat. Cancer 2014, 21, R371–R394. [CrossRef]
31. Greenspan, S.L.; Coates, P.; Sereika, S.M.; Nelson, J.B.; Trump, D.L.; Resnick, N.M. Bone loss after initiation of
androgen deprivation therapy in patients with prostate cancer. J. Clin. Endocrinol. Metab. 2005, 90, 6410–6417.
[CrossRef] [PubMed]
32. Ryan, C.W.; Huo, D.; Stallings, J.W.; Davis, R.L.; Beer, T.M.; McWhorter, L.T. Lifestyle factors and duration
of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of
therapy. Urology 2007, 70, 122–126. [CrossRef] [PubMed]
33. Watts, N.B.; Adler, R.A.; Bilezikian, J.P.; Drake, M.T.; Eastell, R.; Orwoll, E.S.; Finkelstein, J.S. Osteoporosis
in men: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2012, 97, 1802–1822.
[CrossRef] [PubMed]
34. Alibhai, S.M.; Duong-Hua, M.; Cheung, A.M.; Sutradhar, R.; Warde, P.; Fleshner, N.E.; Paszat, L. Fracture
types and risk factors in men with prostate cancer on androgen deprivation therapy: A matched cohort
study of 19,079 men. J. Urol. 2010, 184, 918–923. [CrossRef] [PubMed]
35. Lee, C.E.; Leslie, W.D.; Czaykowski, P.; Gingerich, J.; Geirnaert, M.; Lau, Y.K. A comprehensive bone-health
management approach for men with prostate cancer receiving androgen deprivation therapy. Curr. Oncol.
2011, 18, e163–e172. [CrossRef] [PubMed]
36. Diamond, T.H.; Higano, C.S.; Smith, M.R.; Guise, T.A.; Singer, F.R. Osteoporosis in men with prostate
carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Cancer
2004, 100, 892–899. [CrossRef] [PubMed]
37. Gralow, J.R.; Biermann, J.S.; Farooki, A.; Fornier, M.N.; Gagel, R.F.; Kumar, R.; Litsas, G.; McKay, R.;
Podoloff, D.A.; Srinivas, S.; et al. Nccn task force report: Bone health in cancer care. J. Natl. Compr. Cancar
Netw. 2013, 11 (Suppl. 3), S1–S50; quiz S51. [CrossRef]
38. Nguyen, P.L.; Alibhai, S.M.; Basaria, S.; D’Amico, A.V.; Kantoff, P.W.; Keating, N.L.; Penson, D.F.; Rosario, D.J.;
Tombal, B.; Smith, M.R. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Eur. Urol. 2015, 67, 825–836. [CrossRef]
39. Poon, Y.; Pechlivanoglou, P.; Alibhai, S.M.H.; Naimark, D.; Hoch, J.S.; Papadimitropoulos, E.; Hogan, M.E.;
Krahn, M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications:
Men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.
BJU Int. 2018, 121, 17–28. [CrossRef]
40. Hertel, K.L.; Trahiotis, M.G. Exercise in the prevention and treatment of osteoporosis: The role of physical
therapy and nursing. Nurs. Clin. N. Am. 2001, 36, 441–453.
41. Bosco, C.; Bosnyak, Z.; Malmberg, A.; Adolfsson, J.; Keating, N.L.; Van Hemelrijck, M. Quantifying
observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation
therapy for prostate cancer: A meta-analysis. Eur. Urol. 2015, 68, 386–396. [CrossRef] [PubMed]
42. Guo, Z.; Huang, Y.; Gong, L.; Gan, S.; Chan, F.L.; Gu, C.; Xiang, S.; Wang, S. Association of androgen
deprivation therapy with thromboembolic events in patients with prostate cancer: A systematic review and
meta-analysis. Prostate Cancer Prostatic Dis. 2018. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 113 13 of 13
43. McGinty, H.L.; Phillips, K.M.; Jim, H.S.; Cessna, J.M.; Asvat, Y.; Cases, M.G.; Small, B.J.; Jacobsen, P.B.
Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: A systematic
review and meta-analysis. Support Care Cancer 2014, 22, 2271–2280. [CrossRef] [PubMed]
44. Meng, F.; Zhu, S.; Zhao, J.; Vados, L.; Wang, L.; Zhao, Y.; Zhao, D.; Niu, Y. Stroke related to androgen
deprivation therapy for prostate cancer: A meta-analysis and systematic review. BMC Cancer 2016, 16, 180.
[CrossRef] [PubMed]
45. Nguyen, P.L.; Je, Y.; Schutz, F.A.; Hoffman, K.E.; Hu, J.C.; Parekh, A.; Beckman, J.A.; Choueiri, T.K.
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A
meta-analysis of randomized trials. JAMA 2011, 306, 2359–2366. [CrossRef] [PubMed]
46. Guyatt, G.H.; Oxman, A.D.; Sultan, S.; Glasziou, P.; Akl, E.A.; Alonso-Coello, P.; Atkins, D.; Kunz, R.;
Brozek, J.; Montori, V.; et al. Grade guidelines: 9. Rating up the quality of evidence. J. Clin. Epidemiol.
2011, 64, 1311–1316. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
